Figure 3.

Spectrum of clinical manifestations associated with marked reduction (dihydrorhodamine (DHR) < 10%), slight reduction, and increase of the NOX2 activity. The complete absence of NOX2 activity leads to the development of infectious, inflammatory and autoimmune complications observed in CGD. A partial reduction of the NOX2 activity, observed in female carriers, may lead to the development of autoimmune complications. Upregulation of NOX2 has been observed in different cardiovascular and neurodegenerative disorders and in neoplasms.